Prism1Publications Archives

Models and methods: a perspective of the impact of six IMI translational data-centric initiatives for Alzheimer’s disease and other neuropsychiatric disorders

North et al. (2023): Models and methods: a perspective of the impact of six IMI translational data-centric initiatives for Alzheimer’s disease and other neuropsychiatric disorders. Frontiers in Neurology.

Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and alzheimer’s disease patients

Saris et al. (2022): Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and alzheimer’s disease patients. PLos One, in press.

Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer’s disease

Saris et al. (2021): Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer’s disease. World J Biol Psychiatry.

Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders

De la Torre-Luque et al. (2022): Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry.

Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts

Oliva et al. (2022): Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. Int Clin Psychopharmacol.

Social behavior assessment in cognitively impaired older adults using a passive and remote smartphone application

Muurling et al. (2021): Social behavior assessment in cognitively impaired older adults using a passive and remote smartphone application. Alzheimers and Dementia.

Effect of disease related biases on the subjective assessment of social functioning in Alzheimer’s disease and schizophrenia patients

Jongs et al. (2022): Effect of disease related biases on the subjective assessment of social functioning in Alzheimer’s disease and schizophrenia patients. Journal of Psychiatric Research.

Mismatch negativity as EEG biomarker supporting CNS drug development: a transnosographic and translational study

Loiodice et al. (2021): Mismatch negativity as EEG biomarker supporting CNS drug development: a transnosographic and translational study. Translational Psychiatry.

Preventive strategies for mental health

Arango et al. (2018): Preventive strategies for mental health. Lancet Psychiatry.

Negative symptoms of schizophrenia: new developments and unanswered research questions

Galderisi et al. (2018): Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry.

The PRISM 2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101034377. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA, and Cohen Veterans Bioscience (CVB). The website reflects only the authors' views and IMI JU, EFPIA, CVB, and the European Commission are not responsible for any use that may be made of the information it contains.